Cargando…

Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors

BACKGROUND: CD133 is a marker that identifies/enriches cancer stem cell implicated in tumor initiation. We hypothesize that changes in the CD133 mRNA expression levels and vascular endothelial growth factor (VEGF) may correlate tumor response in GIST. METHODOLOGY/PRINCIPAL FINDINGS: After informed c...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yanhong, Hassan, Manal M., Mo, Jianwen, Lin, Edward H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567095/
https://www.ncbi.nlm.nih.gov/pubmed/23408993
http://dx.doi.org/10.1371/journal.pone.0055520
_version_ 1782258661530271744
author Deng, Yanhong
Hassan, Manal M.
Mo, Jianwen
Lin, Edward H.
author_facet Deng, Yanhong
Hassan, Manal M.
Mo, Jianwen
Lin, Edward H.
author_sort Deng, Yanhong
collection PubMed
description BACKGROUND: CD133 is a marker that identifies/enriches cancer stem cell implicated in tumor initiation. We hypothesize that changes in the CD133 mRNA expression levels and vascular endothelial growth factor (VEGF) may correlate tumor response in GIST. METHODOLOGY/PRINCIPAL FINDINGS: After informed consent, we obtained peripheral blood samples from 24 evaluable patients with gastrointestinal stromal tumors (GIST). There were 7 -paired samples before and after treatment, We measured CD133 mRNA levels by real time RT-PCR method and vascular endothelial growth factor (VEGF) levels by ELISA. All measurements were done in duplicates in two separate experiments. The treatment resulted in significant reduction of CD133 mRNA expression (p = 0.048) as well as the level of VEGF (p = 0.003). The mean CD133 mRNA levels for GIST patients was 615. We found no correlation between the CD133 mRNA levels and VEGF levels. (p = 0.826). Logistic regression analysis suggested a relationship between elevated CD133 mRNA levels and fitted probability of eventual progressive disease (PD) and mixed response at 37% for CD133 mRNA of 2.25, and the probability of eventual PD/MR is 84% for a CD133 of 2072 (p = 0.08). CONCLUSIONS/SIGNIFICANCE: CD133 mRNA expression levels in GIST patients measured by real time RT-PCR assay appeared to correlate with tumor response to surgery or imatinib and may be used to predict tumor progression. Additional prospective studies are warranted.
format Online
Article
Text
id pubmed-3567095
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35670952013-02-13 Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors Deng, Yanhong Hassan, Manal M. Mo, Jianwen Lin, Edward H. PLoS One Research Article BACKGROUND: CD133 is a marker that identifies/enriches cancer stem cell implicated in tumor initiation. We hypothesize that changes in the CD133 mRNA expression levels and vascular endothelial growth factor (VEGF) may correlate tumor response in GIST. METHODOLOGY/PRINCIPAL FINDINGS: After informed consent, we obtained peripheral blood samples from 24 evaluable patients with gastrointestinal stromal tumors (GIST). There were 7 -paired samples before and after treatment, We measured CD133 mRNA levels by real time RT-PCR method and vascular endothelial growth factor (VEGF) levels by ELISA. All measurements were done in duplicates in two separate experiments. The treatment resulted in significant reduction of CD133 mRNA expression (p = 0.048) as well as the level of VEGF (p = 0.003). The mean CD133 mRNA levels for GIST patients was 615. We found no correlation between the CD133 mRNA levels and VEGF levels. (p = 0.826). Logistic regression analysis suggested a relationship between elevated CD133 mRNA levels and fitted probability of eventual progressive disease (PD) and mixed response at 37% for CD133 mRNA of 2.25, and the probability of eventual PD/MR is 84% for a CD133 of 2072 (p = 0.08). CONCLUSIONS/SIGNIFICANCE: CD133 mRNA expression levels in GIST patients measured by real time RT-PCR assay appeared to correlate with tumor response to surgery or imatinib and may be used to predict tumor progression. Additional prospective studies are warranted. Public Library of Science 2013-02-07 /pmc/articles/PMC3567095/ /pubmed/23408993 http://dx.doi.org/10.1371/journal.pone.0055520 Text en © 2013 Deng et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Deng, Yanhong
Hassan, Manal M.
Mo, Jianwen
Lin, Edward H.
Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors
title Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors
title_full Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors
title_fullStr Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors
title_full_unstemmed Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors
title_short Peripheral Blood Mononuclear CD133 mRNA Levels Correlates with Response to Treatment in Patients with Gastrointestinal Stromal Tumors
title_sort peripheral blood mononuclear cd133 mrna levels correlates with response to treatment in patients with gastrointestinal stromal tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567095/
https://www.ncbi.nlm.nih.gov/pubmed/23408993
http://dx.doi.org/10.1371/journal.pone.0055520
work_keys_str_mv AT dengyanhong peripheralbloodmononuclearcd133mrnalevelscorrelateswithresponsetotreatmentinpatientswithgastrointestinalstromaltumors
AT hassanmanalm peripheralbloodmononuclearcd133mrnalevelscorrelateswithresponsetotreatmentinpatientswithgastrointestinalstromaltumors
AT mojianwen peripheralbloodmononuclearcd133mrnalevelscorrelateswithresponsetotreatmentinpatientswithgastrointestinalstromaltumors
AT linedwardh peripheralbloodmononuclearcd133mrnalevelscorrelateswithresponsetotreatmentinpatientswithgastrointestinalstromaltumors